FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194486617> ?p ?o ?g. }

• W3194486617 endingPage "918.e9" @default.
• W3194486617 startingPage "918.e1" @default.
• W3194486617 abstract "Although it is well known that tumor site- or bone marrow-infiltrating regulatory T cells (Tregs) might be correlated with worse outcomes in solid tumors and acute leukemias by promoting immune surveillance escape, their contribution to the immediate post-allogeneic transplantation phase by peripheral blood (PB) allografts remains unclear. Moreover, the Treg content in stem cells harvested from PB has been suggested to be correlated with acute graft versus-host-disease (aGVHD) and immunologic recovery after allogeneic PB stem cell transplantation (allo-PBSCT). This study aimed to investigate the impact of the graft content of Tregs, as graft CD3+/Tregs ratio (gCD3/TregsR), on acute GVHD and post-allo-PBSCT outcomes. We prospectively enrolled 94 consecutive patients at 9 Italian centers of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) with acute myelogenous (n = 71; 75%) or lymphoblastic (n = 23; 25%) leukemia in complete remission who underwent matched related donor (n = 35; 37%) or unrelated donor (n = 59; 63%) allo-PBSCT. The median graft CD3+ cell, Treg, and gCD3/TregsR values were 196 × 106/kg body weight (range, 17 to 666 × 106/kg), 3 × 106/kg (range, 0.1 to 35 × 106/kg), and 71 (range, 1 to 1883), respectively. The discriminatory power of the gCD3/TregsR value to predict grade ≥II aGVHD was assessed by estimating the area under the receiver operating characteristic (ROC) curve (AUC). Any grade and grade ≥II aGVHD occurred in 24 (26%) and 17 (18%) allo-PBSCT recipients, respectively. By ROC analysis, AUC (0.74; 95% confidence interval [CI], 0.608 to 0.866; P = .002) identified 70 as the optimal gCD3/TregsR cutoff value predicting the appearance of grade ≥II aGVHD with 76% sensitivity and 71% specificity. Patients were subdivided into a high (ROC curve value ≥70) gCD3/TregsR group (HR; n = 48) and a low (ROC curve value <70) gCD3/TregsR group (LR; n = 46). The incidence of grade II-IV aGVHD was lower in the LR group compared with the HR group (9% [4 of 46] versus 27% [13 of 48]) in both univariate analysis (odds ratio [OR], 4.8; 95% CI, 1.44 to 16.17; P = .015) and multivariate analysis (OR, 5.0; 95% CI, 1.34 to 18.93; P = .017), whereas no differences were documented taking into account aGVHD of any grade. The overall survival, disease-free survival, nonrelapse mortality, and relapse rates at 2 and 3 years were 61% and 54%, 62% and 55%, 15% and 23%, and 27% and 30%, respectively. Of note, gCD3/TregsR did not significantly correlate with relapse (P = .135). Taken together, our data from this prospective multicenter study confirm the value of Tregs in preventing aGVHD while maintaining the graft-versus-leukemia effect. © 2021 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc." @default.
• W3194486617 created "2021-08-30" @default.
• W3194486617 creator A5004037378 @default.
• W3194486617 creator A5015623905 @default.
• W3194486617 creator A5024394361 @default.
• W3194486617 creator A5031937532 @default.
• W3194486617 creator A5037120320 @default.
• W3194486617 creator A5040478175 @default.
• W3194486617 creator A5042424261 @default.
• W3194486617 creator A5044869604 @default.
• W3194486617 creator A5047101054 @default.
• W3194486617 creator A5057593886 @default.
• W3194486617 creator A5065328889 @default.
• W3194486617 creator A5069571388 @default.
• W3194486617 creator A5070438165 @default.
• W3194486617 creator A5072927664 @default.
• W3194486617 creator A5073711573 @default.
• W3194486617 creator A5084691655 @default.
• W3194486617 creator A5086116060 @default.
• W3194486617 creator A5086479763 @default.
• W3194486617 creator A5089427293 @default.
• W3194486617 date "2021-11-01" @default.
• W3194486617 modified "2023-10-16" @default.
• W3194486617 title "The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation" @default.
• W3194486617 cites W1274344746 @default.
• W3194486617 cites W1584309797 @default.
• W3194486617 cites W1596160021 @default.
• W3194486617 cites W1963899067 @default.
• W3194486617 cites W1981365536 @default.
• W3194486617 cites W1991830316 @default.
• W3194486617 cites W1993798847 @default.
• W3194486617 cites W1996262893 @default.
• W3194486617 cites W1998350666 @default.
• W3194486617 cites W2006756007 @default.
• W3194486617 cites W2014019239 @default.
• W3194486617 cites W2023721800 @default.
• W3194486617 cites W2024958407 @default.
• W3194486617 cites W2025909187 @default.
• W3194486617 cites W2036736974 @default.
• W3194486617 cites W2045254759 @default.
• W3194486617 cites W2051277340 @default.
• W3194486617 cites W2059465100 @default.
• W3194486617 cites W2067564880 @default.
• W3194486617 cites W2068624113 @default.
• W3194486617 cites W2070595325 @default.
• W3194486617 cites W2073137315 @default.
• W3194486617 cites W2074181748 @default.
• W3194486617 cites W2082893937 @default.
• W3194486617 cites W2085530853 @default.
• W3194486617 cites W2085704445 @default.
• W3194486617 cites W2089950573 @default.
• W3194486617 cites W2090123172 @default.
• W3194486617 cites W2099261151 @default.
• W3194486617 cites W2105970563 @default.
• W3194486617 cites W2108010664 @default.
• W3194486617 cites W2109364380 @default.
• W3194486617 cites W2125550036 @default.
• W3194486617 cites W2132289468 @default.
• W3194486617 cites W2141649011 @default.
• W3194486617 cites W2146331182 @default.
• W3194486617 cites W2146821812 @default.
• W3194486617 cites W2147980413 @default.
• W3194486617 cites W2150888933 @default.
• W3194486617 cites W2156964052 @default.
• W3194486617 cites W2157325100 @default.
• W3194486617 cites W2164465286 @default.
• W3194486617 cites W2168628806 @default.
• W3194486617 cites W2178512140 @default.
• W3194486617 cites W2233354089 @default.
• W3194486617 cites W2573156932 @default.
• W3194486617 cites W2999004039 @default.
• W3194486617 cites W3087494818 @default.
• W3194486617 cites W4251022078 @default.
• W3194486617 cites W4313324526 @default.
• W3194486617 doi "https://doi.org/10.1016/j.jtct.2021.08.008" @default.
• W3194486617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34403789" @default.
• W3194486617 hasPublicationYear "2021" @default.
• W3194486617 type Work @default.
• W3194486617 sameAs 3194486617 @default.
• W3194486617 citedByCount "3" @default.
• W3194486617 countsByYear W31944866172022 @default.
• W3194486617 countsByYear W31944866172023 @default.
• W3194486617 crossrefType "journal-article" @default.
• W3194486617 hasAuthorship W3194486617A5004037378 @default.
• W3194486617 hasAuthorship W3194486617A5015623905 @default.
• W3194486617 hasAuthorship W3194486617A5024394361 @default.
• W3194486617 hasAuthorship W3194486617A5031937532 @default.
• W3194486617 hasAuthorship W3194486617A5037120320 @default.
• W3194486617 hasAuthorship W3194486617A5040478175 @default.
• W3194486617 hasAuthorship W3194486617A5042424261 @default.
• W3194486617 hasAuthorship W3194486617A5044869604 @default.
• W3194486617 hasAuthorship W3194486617A5047101054 @default.
• W3194486617 hasAuthorship W3194486617A5057593886 @default.
• W3194486617 hasAuthorship W3194486617A5065328889 @default.
• W3194486617 hasAuthorship W3194486617A5069571388 @default.
• W3194486617 hasAuthorship W3194486617A5070438165 @default.
• W3194486617 hasAuthorship W3194486617A5072927664 @default.
• W3194486617 hasAuthorship W3194486617A5073711573 @default.

• next